Weii @wei7547

@mingchikuo And Apple might as well keep all production in China, the most cost-efficient place. Why bother moving to India at all.

@PIIE The 145% is the sum of 125% reciprocal and 20% fentanyl.

@zerohedge Are the 20% tariffs related to fentanyl exempted?

@PIIE Is it possible 145% is the sum of 125%(reciprocal) and 20% on fentanyl?

@KaiserKuo What a minute... What about the 20% tariffs on fentanyl? Also exempted?

@KobeissiLetter In few more days, other consumer goods will also be exempted. Then 60% of China's exports to the US will be fine. What a victory for Trump

@BillAckman @SecScottBessent @realDonaldTrump Yet, Trump just exempted China's biggest exports to the US (electronics). Indeed, beautiful executed...

MAGA

Liberating Capital Markets - available soon on all streaming platforms that survive the tariff war

Western Biotech’s “DeepSeek Moment” – China’s Rise in Pharma Innovation The WSJ article opens with how Summit Therapeutics’ cancer drug, licensed from China’s Akeso, outperformed Merck’s $30B Keytruda. But apparently this isn't all that special — Chinese companies now account for 31% of major pharma licensing deals, up from just 5% in 2020. How Did China Get Here? The investment bank Stifel listed the below provocative answers they think you'd hear if you asked Chinese biotech CEOs. (Some of these answers seem like they apply to multiple industries, especially #1 & 2.) 1️⃣ You didn't appreciate us. "We worked in your American labs, but you wouldn’t promote us. So we went back to China and built our own companies. Now that you see how good we are, don’t complain." 2️⃣ We run lean and fast. "Your biotechs are bloated with unnecessary FTEs, fancy executive suites, and endless meetings. We focus on innovation, not bureaucracy. You’re paying for overhead, not breakthroughs." OUCH?! 3️⃣ We don’t need to steal your secrets. "Finding novel epitopes and mastering phage display isn’t rocket science. We innovate just like you—except we work harder." 4️⃣ You pushed Wuxi out—we welcomed them back. "You decided Wuxi Biologics was a threat. Fine. Now they focus on our molecules, working faster at a fraction of the cost. Again, don't complain." Why Chinese Biotech Is Winning ✅ Lower costs & streamlined clinical trials ✅ Lean operations with minimal bureaucracy ✅ Better drug candidates at lower prices ✅ Faster R&D with Wuxi and other CDMOs driving efficiency Global Pharma’s Growing Dependence on China - Nearly a third of licensed molecules in 2023-2024 came from China. - VEGF x PD-1, a major oncology breakthrough for solid tumors, originated in China, where research remains ahead of Western counterparts. - China is rapidly advancing first-in-class biologics and fundamental life sciences research. Finally, efforts to cut off China (e.g., BioSecure Act) are losing momentum, as they offer little national security benefit. What This Means for Western VC & Biotech Chinese biotech isn’t just competing—it’s delivering better drugs at lower prices. If this trend continues, industry experts are predicting it could disrupt the U.S. biotech funding model, as VCs struggle to justify sky-high valuations when superior alternatives are available for less. Meanwhile, India is also entering the game, adding to the competition. I’m no biotech expert, but after loosely following the industry for the past two years, this WSJ headline doesn’t surprise me. A decade ago, when LPs asked me to look into China’s then-nonexistent biotech sector, I never could have predicted its rapid rise. What’s more surprising—and disappointing—is seeing the U.S., once the gold standard for efficiency, now bogged down in the kind of bureaucracy I used to associate with China. But as a consumer, I’m excited to see China, India, and others join the race for better drugs. Links below in comments.

This is the quality of humor we want from Grok

@dizzyhitman_007 @MacroPoloChina I wonder too. More so that I cannot believe India is nowhere on this chart...

@AsiaFinance 然后到了一点，外循环开始招人厌，就是卡壳了

@AsiaFinance 不是悖论，是政策选择。东亚经济都是政策上长期以压低居民收入为代价大力支持制造业，自然内循环不起来。

Chinese long-term thinking demonstrated. Like when they planted the seeds of the EV industry in 2010 and no one took note but everyone else thought its enough to start to compete in 2020. Wild. 😂

@HAOHONG_CFA It's a self-imposed dilemma. Why not support consumption?

@AgatheDemarais @ecfr Talking about selective interpretation, the share of "unlikely" in China is similar to that in Europe. What do you make of that?

Why Xi tried to assure U.S. he has no plans for Taiwan invasion 1/ The No. 1 takeaway from the Biden-Xi summit was that the Chinese leader said, in no uncertain terms, that Beijing has no plans for an invasion of Taiwan in 2027 or 2035. asia.nikkei.com/Politics/Inter… via @NikkeiAsia

@KaiserKuo So very sorry to hear that. Your work is THE best on understanding China for its objectivity and balanced views. This is sad that the world force us just to take a side...